Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

More About the REPEAT Study

Enrolling 950 patients from Europe, North America and Latin America, REPEAT (REtreatment with PEgasys in pATients Not Responding to Peg-Intron Therapy) was designed to explore whether intensified treatment with a higher fixed-dose induction of PEGASYS in combination with COPEGUS and/or longer treatment duration may increase treatment success rates in patients who didn't respond to at least twelve weeks of Peg-Intron/ribavirin combination therapy. Patients were randomized 2:1:1:2 to one of four regimens:

-- Patients in arms A (n=318) and B (n=158) received PEGASYS 360 mcg/week

for 12 weeks, followed by 180 mcg/week for a further 60 or 36 weeks,

respectively

-- Patients in arms C (n=158) and D (n=316) received PEGASYS 180 mcg/week

for 72 or 48 weeks, respectively

-- All patients received COPEGUS (1,000/1,200 mg/day) in combination with

PEGASYS

Results showed:

-- The primary endpoint was met: SVR, defined by undetectable hepatitis C

virus RNA in the blood six months after the end of treatment, was

significantly higher for arm A (16 percent) compared to arm D (nine

percent)

-- A pooled analysis of the 72-week arms vs. the 48-week arms showed that

72 weeks of treatment had the biggest impact on success of treatment,

with a doubling of SVR rate compared to 48 weeks (16 percent vs. eight

percent). A pooled analysis of the induction dose arms vs. standard

dose arms showed that treatment with higher fixed-dose induction for

this difficult-to-treat patient population did not provide significant

additional benefit

-- Response at 12 weeks was a strong predictor of successful treatment

-- Of patients whose virus was undetectable after 12 weeks of therapy,

57 percent in the 72-week arms went on to achieve treatment success

(by comparison, among patient
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2012  Pharmaceutical marketers who need to calibrate multi-channel marketing ... limitless questions. SyntheSight™ , a new ... with a patent-pending IntelliScore™ , provides ... leaders find answers. SyntheSight ...
... the fastest growing Electronic Medical Record ... its award winning e-prescribing software has been revamped; ... experience based on community feedback. The company,s free ... interactions for medical professionals in 2011 alone. ...
Cached Medicine Technology:RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 2RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 3Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... the same protein that was a primary mediator of the birth ... multiple myeloma , says the study,s senior investigator, Keith ... Dr. Stewart presented the results at the 53rd annual meeting of ... The drug thalidomide achieved infamy in the early 1960s as the ...
... December 10, 2011) Symptoms improved significantly in adults ... treatment with gene therapy developed by researchers at St. ... be safe in a clinical trial conducted at the ... findings of the six-person study mark the first proof ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is ... protect your health during the flu season, but too few ... shrug off concerns about the flu, yet every year it ... 200,000 to the hospital and killing thousands," Dr. Thomas Slama, ...
... so many postmenopausal women who are treated for estrogen-sensitive ... disease from recurring? The first study to actually ... largest, most scientifically rigorous study to examine the question ... of the medications, side effects, which are more severe ...
... present in dangerous quantities in the Vauchre river basin ... be presented the 9th of December, at the American ... to kill microorganisms, called biocides, are added to exterior ... Washed off of building facades during heavy rains, however, ...
... 9 (HealthDay News) -- ,Preschool children who were born just ... behavioral and emotional problems, new research suggests. Researchers in ... development tests on about 1,500 children when they were 4 ... and nearly 1,000 were born between 32 and 35 weeks ...
Cached Medicine News:Health News:Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Why women quit breast cancer drugs early 2Health News:Why women quit breast cancer drugs early 3Health News:Model shows how façade pollutants make it into the environment 2Health News:Behavior Problems May Surface in Preemies by Preschool 2
... ExTOL systems feature your choice of ... electrocardiographs, an easy-to-operate monitor and the ... exercise stress testing systems also feature ... point, pre-programmed or custom protocols, and ...
... w/ Remote/Controller. Includes Full Range ... Children. Multiple 20/20 slides. Polarized ... allows you to customize your slide choices. ... with Long Life. Variety of mounting options. ...
... Ultimate in Stability. ... stabilizer features superior arm ... in the clamp/turret mechanism. ... features the ultimate flexibility ...
... leader in beating heart bypass, comes the ... NS device is the first leap in ... of surgical revascularization.,The Starfish NS Heart Positioner ... Small Thoracotomy (MVST) procedure without CPB and ...
Medicine Products: